Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial. Shi Y, Fang J, Xing L, Yao Y, et al. Nat Med 2025 Jan 6. doi: 10.1038/s41591-024-03401.

Read + Share

Amedeo Smart

Independent Medical Education

Shi Y, Fang J, Xing L, Yao Y, et al. Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial. Nat Med 2025 Jan 6. doi: 10.1038/s41591-024-03401.
PMID: 39762419